Top

Published in:

01-06-2018 | Original Paper

Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy

Authors: Amelie Burghardt, Frank van Buuren, Zisis Dimitriadis, Tim Grübbel, Hubert Seggewiss, Smita Scholtz, Dieter Horstkotte, Lothar Faber

Published in: Clinical Research in Cardiology | Issue 6/2018

Abstract

Background and study objective

Different studies have shown a good long-term survival with improvement of symptoms and hemodynamics after percutaneous septal ablation (PTSMA), similar to myectomy considered to be the therapeutic “gold standard” for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). Furthermore, desobliteration of left ventricular (LV) outflow may modify features of the disease considered to be risk-relevant, such as magnitude of LV hypertrophy, outflow gradient, and left atrial (LA) size. The aim oft this study was to examine predictors of long-term mortality in a large cohort of patients with HOCM treated with PTSMA.

Methods and results

497 consecutive patients with symptomatic HOCM (mean age 55.4 ± 14.4 years, NYHA class: 2.9 ± 0.4) who underwent PTSMA between 1996 and 2014 were studied. Periprocedural mortality was 1% (five patients). During a follow-up time of 64.5 ± 53.2 months (range 0.1–207), 51 patients died, of these 25 due to cardiovascular problems, while 26 deaths were attributed to non-cardiac causes. Overall survival rates were 89.4% (± 1.7) after 5 and 80.6% (± 2.7) after 10 years. Among the baseline variables, advanced age, recurrent syncope, and magnitude of LV thickening were risk markers correlated to long-term post-procedural survival. The only mortality predictor that could be identified during follow-up was post-procedural NYHA class. Neither the other classical HCM risk markers nor other clinical or echocardiographic parameters predicted cardiac or all-cause mortality in this cohort.

Conclusions

Our findings suggest that the risk profile after septal ablation may differ from that of HOCM patients without an outflow desobliteration.

Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214CrossRefPubMed

Braunwald E (1997) Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy. Circulation 95:1981–1982CrossRefPubMed

Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, Redwood DR (1975) Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52:88–102CrossRefPubMed

Maron BJ, Epstein SE, Morrow AG (1983) Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 4(Suppl F):175–185CrossRefPubMed

Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:470–476CrossRefPubMed

Schulte HD, Gramsch-Zabel H, Schwartzkopff B (1995) Hypertrophische obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wochenschr 125:1940–1949PubMed

Watkins H, McKenna WJ (2005) The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:477–479CrossRefPubMed

Leonardi RA, Kransdorf EP, Simel DL, Wang A (2010) Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 3:97–104CrossRefPubMed

Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quiñones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1701–1706CrossRefPubMed

10.

Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55:823–834CrossRefPubMed

11.

Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L (2007) Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 96:856–863CrossRefPubMed

12.

Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H (2016) Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 105:953–961CrossRefPubMed

13.

Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 96:864–873CrossRefPubMed

14.

Faber L, Gleichmann U, Horstkotte D, Seggewiss H (2017) Catheter-based septal ablation for hypertrophic obstructive cardiomyopathy: long-term follow-up 1996–2016. Dtsch Med Wochenschr 142:276–281CrossRefPubMed

15.

Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31:252–258CrossRefPubMed

16.

Faber L, Seggewiss H, ^, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, Seipel L, Horstkotte D (2005) Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol 94: 516 – 23CrossRefPubMed

17.

Faber L, Seggewiss H, Ziemssen P, Gleichmann U (1999) Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv 47:462–466CrossRefPubMed

18.

Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol 119:163–167CrossRefPubMed

19.

Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415–2421CrossRefPubMed

20.

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS,. Naidu SS, Rick A. Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary. Circulation 124:2761–2796CrossRefPubMed

21.

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H, members ATF (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed

22.

Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212–2218CrossRefPubMed

23.

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NAM, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P (2007) Implantable Cardioverter–defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405–412PubMed

24.

Frommeyer G, Dechering DG, Zumhagen S, Löher A, Köbe J, Eckardt L, Reinke F (2016) Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol 105:89–93CrossRefPubMed

25.

Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, Bitter T, Vogt J, van Buuren F, Bogunovic N, Horstkotte D, Faber L (2013) Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol 29:358–363CrossRefPubMed

26.

Buck T, Breithardt OA, Faber L, Fehske W, Flachskampf FA, Franke A, Hagendorff A, Hoffmann R, Kruck I, Kücherer H, Menzel T, Pethig K, Tiemann K, Voigt JU, Weidemann F, Nixdorff U (2009) Manual zur Durchführung der Echokardiographie. Clin Res Cardiol 4:Suppl 1

27.

Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in m-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083CrossRefPubMed

28.

Panza JA, Petrone RK, Fananapazir L, Maron BJ (1992) Utility of continuous wave doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 19:91–99CrossRefPubMed

29.

Watkins H (1994) Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J 72:4–9CrossRef

30.

Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE (1998) Mutations in the gene for cardiac myosin-binding protein c and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338:1248–1257CrossRefPubMed

31.

Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232–2239CrossRefPubMed

32.

Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778–1785CrossRefPubMed

33.

Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295–303CrossRefPubMed

34.

Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, Bundgaard H (2013) Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 99:1012–1017CrossRefPubMed

35.

Veselka L, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, Dabrowski M, Hansen PR, Almaas VM, Seggewiss H, Horstkotte D, Tomasov P, Adlova R, Bundgaard H, Steggerda R, ten Berg J, Faber L (2016) Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 37:1517–1523CrossRefPubMed

Title: Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy
Authors: Amelie Burghardt
Frank van Buuren
Zisis Dimitriadis
Tim Grübbel
Hubert Seggewiss
Smita Scholtz
Dieter Horstkotte
Lothar Faber
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 6/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-018-1209-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy

Abstract

Background and study objective

Methods and results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and study objective

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock—a substudy of the IABP-SHOCK II-trial

Correction to: Prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock—a substudy of the IABP-SHOCK II-trial

Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study

Correction to: Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation

Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation

The contribution of comorbidities to mortality in hospitalized patients with heart failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page